Skip to main content
OpenTrials
Completed

NCT Number: NCT05246540

Evaluation of PET/CT of Cephalic Arteries for the Diagnosis of Giant Cell Arteritis

Giant cell arteritis (GCA) is the most common vasculitis in adults. The diagnosis of GCA is evoked by the association of clinical signs and biological anomalies (inflammatory syndrome) in patients over 50 years of age. On the other hand, starting a treatment implies being certain of the diagnosis which requires performing a temporal artery biopsy under local anesthesia. This examination is therefore an invasive procedure for patients whose sensitivity is not optimal. This is why imaging techniques (echo-Doppler or MRI of the temporal arteries) have been developed to look for signs of vasculitis without the need to perform a biopsy. However, these examinations lack sensitivity (=falsely concluding the absence of GCA) and specificity (=falsely concluding the presence of GCA). Recently, advances in imaging, and in particular positron emission tomography (PET), have made it possible to visualize the cephalic arteries, including the temporal artery.

The aim of this study is therefore to evaluate the sensitivity and specificity of PET of the cephalic arteries for the diagnosis of GCA and to compare them with those of echo-Doppler and MRI of the temporal arteries.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Any patient for which the diagnosis of GCA is suspected and who underwent a cervical PET/CT

Exclusion criteria

  • previously diagnosed GCA, glycemia > 7 mmol/L, PET CT performed more than 72 h after introduction of glucocorticoids, age < 50 years

Treatment and study plan

Data Collection

Other

Data collection

Primary outcomes

  1. Sensitivity / specificity of cervical PET/CT for the diagnosis of GCA

    Time frame: 6 months

    diagnosis retained by the clinician without question after 6 months of follow-up and treatment for at least 6 consecutive months

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire Dijon

Other

Registry information

Acronym: Cervico-TEP et

Important dates

Study start
2020
Primary completion
2020
Study completion
2021
First posted
Feb 18, 2022
Registry last updated
Jan 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.